A detailed history of Exane Derivatives transactions in Guardant Health, Inc. stock. As of the latest transaction made, Exane Derivatives holds 69 shares of GH stock, worth $1,848. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69
Previous 884 92.19%
Holding current value
$1,848
Previous $58,000 96.55%
% of portfolio
0.0%
Previous 0.02%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 12, 2022

SELL
$28.82 - $77.35 $23,488 - $63,040
-815 Reduced 92.19%
69 $2,000
Q1 2022

Apr 22, 2022

SELL
$48.25 - $100.49 $8,540 - $17,786
-177 Reduced 16.68%
884 $58,000
Q4 2021

Jan 28, 2022

SELL
$88.71 - $120.43 $124,637 - $169,204
-1,405 Reduced 56.97%
1,061 $106,000
Q3 2021

Oct 26, 2021

SELL
$98.77 - $132.17 $22,322 - $29,870
-226 Reduced 8.4%
2,466 $308,000
Q2 2021

Jul 28, 2021

SELL
$109.77 - $165.68 $57,299 - $86,484
-522 Reduced 16.24%
2,692 $334,000
Q1 2021

Apr 30, 2021

SELL
$127.04 - $179.1 $177,093 - $249,665
-1,394 Reduced 30.25%
3,214 $490,000
Q4 2020

Jan 27, 2021

BUY
$99.96 - $135.93 $287,684 - $391,206
2,878 Added 166.36%
4,608 $593,000
Q3 2020

Oct 06, 2020

BUY
$80.32 - $111.8 $138,953 - $193,414
1,730 New
1,730 $193,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $2.74B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.